FT-819

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NameFT-819
Drug Alias Name1XX CAR19 T-cell therapy (Fate Therapeutics)hiPSC-derived TCR-less TRAC-CAR19 T cells (Fate Therapeutics)FT-8198FT-819FT 8198
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-TRBC1Anti-CD19
TargetsTRBC1B-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A